Marye J. Boers‐Sonderen

Author

Also Known As

Christina A. Hulsbergen-van de Kaa, M.J. Boers-Sonderen, Marye J. Boers-Sonderen, Marye Boers-Sonderen, Marye J Boers-Sonderen, Marye J. Boers-Sonderen, Marye J. Boers‐Sonderen

124

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Radboud University Medical Center The Netherlands Cancer Institute University Medical Center Utrecht Isala

About

Marye J. Boers‐Sonderen is an author at Radboud University Nijmegen specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	527
2	Immunology	5	5	147
3	Health Sciences	2	2	152
4	Health Policy	1	1	10
5	Obstetrics	1	1	31

Marye J. Boers‐Sonderen

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, New England Journal of Medicine	2022	474
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, NEJM Evidence Surgical OncologyDistant MetastasisMedicineAdjuvant PembrolizumabMelanoma	2022	142
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Monique K. van der Kooij, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Annals of Internal Medicine	2021	103
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma Olivier J. van Not, Rik J. Verheijden, Alfonsus Johannes Maria van den Eertwegh, JAMA Oncology	2022	99
Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma Marye J. Boers‐Sonderen, Tim J. van Oostenbrugge, Otto C. Boerman, European Urology UrologyGenitourinary CancerMedicineCancer TreatmentPhase 2	2015	96
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, European Journal of Cancer MedicineMelanomaImmunologySeven-year AnalysisImmune Checkpoint Inhibitor	2024	60
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, European Journal of Cancer	2022	56
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, European Journal of Cancer Checkpoint Inhibitor EffectivenessMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2024	44
Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response Monique K. van der Kooij, Marjolein J.A.L. Wetzels, Maureen J.B. Aarts, Cancers	2020	41
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients Maaike Biewenga, Monique K. van der Kooij, Michel W.J.M. Wouters, Hepatology International	2021	38

Page 1